期刊文献+

卵巢癌患者糖链抗原125关联性及预后研究 被引量:1

Study on the association and prognosis of CA125 in patients with ovarian cancer
下载PDF
导出
摘要 目的:探讨卵巢癌患者肿瘤标志物糖链抗原125(CA125)、糖链抗原153(CA153)、糖链抗原50(CA50)、谷氨酰转肽酶(γ-GGT)、乳酸脱氢酶(LDH)﹑α-羟丁酸脱氢酶(α-HBDH)的关联性及预后影响因素。方法:选择2016年1月—2018年5月收治的卵巢癌患者98例,根据CA125水平分为阳性组(CA125≥35 U/mL)45例,阴性组(CA125<35 U/mL)53例。比较两组血清CA125,CA153,CA50,γ-GGT,LDH,α-HBDH水平,评估CA125与各指标之间的相关性,并分析可能对卵巢癌患者预后有影响的11个因素。通过门诊复查﹑电话随访,获得患者是否死亡及死亡时间等信息,采用Kaplan-Meier进行单因素分析,Cox回归进行多因素分析。结果:两组CA153,LDH,α-HBDH比较,差异有统计学意义(P<0.05);两组CA50和γ-GGT比较,差异无统计学意义(P>0.05)。Cox模型多因素分析结果显示,CA125水平与治疗方法为卵巢癌患者生存预后的危险因素。结论:CA125与CA153,LDH,α-HBDH联合检测对提高卵巢癌患者早期诊断﹑疗效监测及预后判断具有重要意义。CA125水平与治疗方法是影响卵巢癌患者生存的重要影响因素。 Objective:To explore the level of tumor marker sugar chain antigen 125(CA125)in patients with ovarian cancer and sugar chain antigen 153(CA153),sugar chain antigen 50(CA50),glutamyl transpeptidase(γ-GGT),lactate dehydrogenase(LDH),α-hydroxybutyrate dehydrogenase(α-HBDH)correlation and analysis of prognostic factors.Methods:From January 2016 to May 2018,98 patients with ovarian cancer were selected in the oncology department.According to the level of CA125,they were divided into positive group(CA125≥35 U/mL)45 cases,and negative group(CA125<35 U/mL)53 cases.The serum levels of CA125,CA153,CA50,γ-GGT,LDH,α-HBDH in each group were compared,Assess the correlation between CA125 and various indicators WERE evaluated,and 11 factors that may have an impact on the prognosis of patients with ovarian cancer were analyzed.Through outpatient review and telephone follow-up,information about whether the patient died and the time of death were obtained.Kaplan-Meier was used for univariate analysis,and Cox regression was used for multivariate analysis.Results:The CA153,LDH,andα-HBDH in the positive group were significantly different from the negative group(P<0.05),and there was no significant difference in CA50,γ-GGT(P>0.05).Cox model multivariate analysis results show that CA125 and treatment methods are independent risk factors affecting the prognosis of this group of ovarian cancer patients.Conclusion:CA153,LDH,andα-HBDH are important factors that affect the level of CA125.Treatment methods and CA125 levels are independent risk factors affecting the prognosis of patients with ovarian cancer.
作者 柯柳华 张红雨 梁卡 易娟 KE Liuhua;ZHANG Hongyu;LIANG Ka;YI Juan(Liuzhou Traditional Chinese Medicine Hospital,Liuzhou 545001,China)
机构地区 柳州市中医医院
出处 《临床医药实践》 2021年第10期723-727,共5页 Proceeding of Clinical Medicine
基金 广西壮族自治区卫生和计划生育委员会科研课题(项目编号:Z20180371)。
关键词 卵巢癌 糖链抗原125 糖链抗原153 糖链抗原50 谷氨酰转肽酶 乳酸脱氢酶 Α-羟丁酸脱氢酶 影响因素 预后 ovarian cancer sugar chain antigen 125 sugar chain antigen 153 sugar chain antigen 50 glutamyl transpeptidase lactate dehydrogenase α-butyrate dehydrogenase influencing factors prognosis
  • 相关文献

参考文献7

二级参考文献78

  • 1潘秀琴,葛金莲,边红星.五项血清酶对肺癌胃癌的诊断价值评价[J].新疆医科大学学报,2005,28(7):664-664. 被引量:2
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4) : 225 -249.
  • 3Gubbels JA, Clanssen N, Kapur AK, et al. The detection, treat- ment, and biology of epithelial ovariancancer [ J ]. J Ovarian Res, 2010, 3(8) : 1 -11.
  • 4Donach M, Yu Y, Artioli G, et al. Combined use of biomarkers for detection of ovarian cancer in high - risk women [ J ]. Tumour Biol, 2010, 31(3) : 209 -215.
  • 5Thylan S. Prospective multieenter study on CA 125 in postmenopans- al pelvic masses[J]. Gynecol Oncol, 1995, 58(2) : 281 -283.
  • 6Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic mark- er for ovarian cancer[ J]. Cancer Lett, 2007, 249 ( 1 ) : 14 - 17.
  • 7Lenhard MS, Nehring S, Nagel D, et al. , Predictive value of CA 125 and CA 724 in ovarian borderline tumors[J]. Clin Cbem Lab Med, 2009, 47(5) : 537 -542.
  • 8Moore RG, MacLaughlan S, Bast RC. Current state of biomarker de- velopment for clinical application in epithelial ovarian cancer [ J ]. Gynecol Oncol, 2010, 116(2) : 240 -245.
  • 9Kelly PJ, Archbold P, Price JH, et al. Serum CA199 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype[J]. J Clin Pathol, 2010, 63(2) : 169 -173.
  • 10Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens [J]. Cancer Prev Res (Phila), 2011, 4: 365-374.

共引文献217

同被引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部